| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H73NO16 |
| Molecular Weight | 884.0582 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 26 / 26 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]6(CC[C@@H](C)CN6)O2)O[C@]7([H])O[C@H](CO)[C@H](O)[C@H](O[C@]8([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@]9([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O
InChI
InChIKey=QCTMYNGDIBTNSK-XEAAVONHSA-N
InChI=1S/C45H73NO16/c1-19-8-13-45(46-16-19)20(2)30-27(62-45)15-26-24-7-6-22-14-23(9-11-43(22,4)25(24)10-12-44(26,30)5)57-42-39(61-40-36(54)34(52)31(49)21(3)56-40)38(33(51)29(18-48)59-42)60-41-37(55)35(53)32(50)28(17-47)58-41/h6,19-21,23-42,46-55H,7-18H2,1-5H3/t19-,20+,21+,23+,24-,25+,26+,27+,28-,29-,30+,31+,32-,33+,34-,35+,36-,37-,38+,39-,40+,41+,42-,43+,44+,45-/m1/s1
| Molecular Formula | C45H73NO16 |
| Molecular Weight | 884.0582 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 25 / 26 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Solasonine, a known glycoalkaloid, is a potential anti-cancer agent. Solasonine is a component of Curaderm BEC5 indicated for the topical treatment of actinic keratosis, keratoacanthoma, basal cell carcinoma and cutaneous superficial squamous cell carcinoma. BEC is a standardized mixture of Solamargine (33%), Solasonine (33%) and di-and monoglycosides of solasodine (34%) extracted from S. sodomaeum, now reclassified as S. linnaeanum. Solasonine could inhibit cell proliferation, migration and colony formation of glioma cells. Treatment of solasonine induced apoptosis via modulating cytochrome c and caspase signaling. Besides, solasonine decreased the expression of proinflammatory mediators and nuclear translocalization of NF-κB p50/p65. Mechanistic investigation further revealed that solasonine may target anti-inflammatory signaling pathway, and more specifically p-p38 and p-JNK MAPKs.
Originator
Approval Year
PubMed
Sample Use Guides
Curaderm BEC5, 0.005% BEC for topical use. BEC is a standardized mixture of Solamargine (33%), Solasonine (33%) and di-and monoglycosides of solasodine (34%) extracted from S. sodomaeum, now reclassified as S. linnaeanum.
• For topical use only; not for oral, ophthalmic, or intravaginal use. (2)
• Actinic Keratosis: Apply Curaderm BEC5 to the affected area with an occlusive dressing, twice daily for 3 consecutive days. (2)
• Keratoacanthoma, basal cell carcinoma and cutaneous superficial squamous cell carcinoma:
Apply Curaderm BEC5 only to the lesion with an occlusive dressing, twice daily until lesion is completely cleared (2)
Route of Administration:
Topical
